|Articles|November 14, 2012

Stereotactic body RT efficacious in localized PCa

Stereotactic body radiotherapy appears to be an effective treatment option for patients with organ-confined prostate cancer, according to two separate studies presented at the American Association for Radiation Oncology annual meeting in Boston.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Register now!

Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Multimedia

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Multimedia

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Multimedia

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Stereotactic body RT efficacious in localized PCa

Newsletter

Related Content

UGN-103 positioned as next step in intravesical therapy for LG-IR-NMIBC

NMIBC treatment success: Why less frequent dosing and adherence matter

FDA approves flibanserin for hypoactive sexual desire disorder in postmenopausal women

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

DSUI Urology on the Beach

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Trending on Urology Times

FDA approves flibanserin for hypoactive sexual desire disorder in postmenopausal women

FDA approves first-line Zenflow system for the treatment of BPH

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men